Axial Spondyloarthritis

Treat-to-target tapering of TNF inhibitors in patients with psoriatic arthritis or axial spondyloarthritis does not result in any negative impact on disease activity, compared with the full dose, according to data published in Rheumatology.

Upadacitinib significantly reduced signs and symptoms of both ankylosing spondylitis and nonradiographic axial spondyloarthritis, as well as improved physical function and disease activity, according to a pair of phase 3 studies from AbbVie.

Secukinumab improves non-radiographic axial spondyloarthritis signs and symptoms across patients grouped by C-reactive protein level, MRI score, HLA-B27 status and sex, according to data published in Arthritis Research & Therapy.

In contrast to some previous studies, an analysis of U.S. Army personnel found that the incidence of ankylosing spondylitis was similar between men and women, according to data published in Arthritis Care & Research.

Primary care providers reported a lack of familiarity with axial spondyloarthritis features, contributing to fewer rheumatology referrals and a delay in diagnosis, noted a presenter at the 2021 North American Young Rheumatology Investigator Forum.

Partnerships between rheumatologists and specially trained advanced practice providers in primary care can reduce diagnostic delay and shorten wait times in axial spondyloarthritis, according to data published in Arthritis Care & Research.

Secukinumab and etanercept are associated with an increased risk for anterior uveitis in patients with spondyloarthritis, compared with monoclonal TNF inhibitors, according to data published in the Annals of the Rheumatic Diseases.

Guselkumab administered once every 4 or 8 weeks improved axial outcomes in patients with psoriatic arthritis who have sacroiliitis through week 52, according to data published in The Lancet Rheumatology.

Most patients with active, radiographic axial spondyloarthritis who receive ixekizumab for 2 years show no radiographic disease progression, with low mean progression overall, according to a poster presentation at the EULAR 2021 Congress.

European patients with axial spondyloarthritis wait an average of more than 7 years between the first appearance of symptoms and receiving a diagnosis, according to data published in Rheumatology.